GCGR

General Catalyst Global Resilie

Near 52W High

$10.18$0.01 (-0.10%)

Loading Chart...

Institutional Signal // Day Trade Edge:Neutral / No Active Setup Today

Scan Active Universe on Day Trade Edge

Key Statistics

Market Cap514.71M

Forward P/E—

EPS (TTM)—

52-Week Return-0.39%

50-Day Moving Avg$10.14

200-Day Moving Avg$10.14

Volume Today2.01K

Avg Volume89.19K

Day Range$10.17 – $10.18

52-Week Range$9.96 – $10.22

Open Price$10.17

Previous Close$10.19

Company Profile

Description

General Catalyst Global Resilience Merger Corp. focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2026 and is based in Cambridge, Massachusetts.

Sector

Financial Services

Industry

Shell Companies

CEO

Mr. Paul S. Kwan

Website

globalresiliencemergercorp.com

SEC Filings

EDGAR Filings

Exchange Listing

Nasdaq.com

Company Profile

Description

Sector

Financial Services

Industry

Shell Companies

CEO

Mr. Paul S. Kwan

Website

globalresiliencemergercorp.com

SEC Filings

EDGAR Filings

Exchange Listing

Nasdaq.com

GCGR

Key Statistics

Company Profile

Company Profile

Recent News

MTVA: Dose Titration Complete in Phase 1 Part 3 Study of DA-1726

Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist ASC35

MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Ascletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule GLP-1/GIP/Amylin Fixed-Dose Combination

Ascletis Announces Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model

Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting

Ascletis Selects for Clinical Development a Fixed-Dose Combination of First-in-Class Oral Small Molecule GIPR Agonist, ASC48, and Oral Small Molecule GLP-1R Agonist, ASC30

MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity

Recent News

Company Profile

Recent News

MTVA: Dose Titration Complete in Phase 1 Part 3 Study of DA-1726

Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist ASC35

MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Ascletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule GLP-1/GIP/Amylin Fixed-Dose Combination

Ascletis Announces Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model

Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting

Ascletis Selects for Clinical Development a Fixed-Dose Combination of First-in-Class Oral Small Molecule GIPR Agonist, ASC48, and Oral Small Molecule GLP-1R Agonist, ASC30

MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity